104 related articles for article (PubMed ID: 27878835)
1. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G; Ysebaert L; Nguyen-Thi PL; Lepretre S; Quinquenel A; Dupuis J; Lemal R; Aurran T; Tomowiak C; Cymbalista F; Dilhuydy MS; Brion A; Morel P; Cazin B; Leblond V; Cartron G; Ré D; Béné MC; Michallet AS; Feugier P
Hematol Oncol; 2017 Dec; 35(4):671-678. PubMed ID: 27878835
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Österborg A; Hansson L
Br J Haematol; 2020 Nov; 191(3):426-432. PubMed ID: 32779190
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL).
Ma H; O'Brien S; Gupta P
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):77-82. PubMed ID: 37743181
[TBL] [Abstract][Full Text] [Related]
4. A good outcome.
Wildes TM; Fabbiano K
J Geriatr Oncol; 2024 May; ():101794. PubMed ID: 38755039
[No Abstract] [Full Text] [Related]
5. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
[TBL] [Abstract][Full Text] [Related]
6. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
7. Sequencing of chronic lymphocytic leukemia therapies.
Barrientos JC
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy of CLL.
Al-Sawaf O; Fischer K; Eichhorst B; Hallek M
Oncol Res Treat; 2016; 39(12):768-778. PubMed ID: 27889784
[TBL] [Abstract][Full Text] [Related]
9. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2017 Feb; 16(2):185-201. PubMed ID: 27880061
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Robak T; Hellmann A; Kloczko J; Loscertales J; Lech-Maranda E; Pagel JM; Mato A; Byrd JC; Awan FT; Hebart H; Garcia-Marco JA; Hill BT; Hallek M; Eisenfeld AJ; Stromatt SC; Jaeger U
Br J Haematol; 2017 Feb; 176(4):618-628. PubMed ID: 27977057
[TBL] [Abstract][Full Text] [Related]
11. Prognostication of chronic lymphocytic leukemia in the era of new agents.
Eichhorst B; Hallek M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
[TBL] [Abstract][Full Text] [Related]
12. First-line therapy for young patients with CLL.
Jain N; O'Brien S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):146-148. PubMed ID: 27913473
[TBL] [Abstract][Full Text] [Related]
13. Novel agents in chronic lymphocytic leukemia.
Lamanna N; O'Brien S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
[TBL] [Abstract][Full Text] [Related]
14. The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.
Ortíz-Maldonado V; Mozas P; Delgado J
Ther Adv Hematol; 2016 Dec; 7(6):321-329. PubMed ID: 27904736
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia.
Nazir A; Fawad ; Ali S; Badar F; Siddique N; Hameed A
Pak J Med Sci; 2016; 32(5):1213-1217. PubMed ID: 27882024
[TBL] [Abstract][Full Text] [Related]
16. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
17. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Sharman JP; Farber CM; Mahadevan D; Schreeder MT; Brooks HD; Kolibaba KS; Fanning S; Klein L; Greenwald DR; Sportelli P; Miskin HP; Weiss MS; Burke JM
Br J Haematol; 2017 Feb; 176(3):412-420. PubMed ID: 27982425
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.
Tees MT; Flinn IW
Expert Rev Hematol; 2017 Feb; 10(2):137-146. PubMed ID: 27936980
[TBL] [Abstract][Full Text] [Related]
19. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]